Catalyst Pharmaceuticals Inc’s filing revealed that its Chief Med. & Reg. Officer INGENITO GARY unloaded Company’s shares for reported $3.9 million on Mar 06 ’25. In the deal valued at $21.67 per share,180,096 shares were sold. As a result of this transaction, INGENITO GARY now holds 68,873 shares worth roughly $1.7 million.
Then, INGENITO GARY sold 44,904 shares, generating $991,929 in total proceeds. Upon selling the shares at $22.09, the Chief Med. & Reg. Officer now owns 68,873 shares.
Before that, INGENITO GARY bought 180,096 shares. Catalyst Pharmaceuticals Inc shares valued at $3,903,251 were divested by the Officer at a price of $21.67 per share.
Robert W. Baird initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to an Outperform in a research note published on February 04, 2025; the price target was $28. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid November with a ‘”an Overweight”‘ rating. Citigroup began covering CPRX with “Buy” recommendation on March 14, 2024. BofA Securities started covering the stock on March 07, 2024. It rated CPRX as “a Buy”.
Price Performance Review of CPRX
On Friday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock fall -0.60% to $24.69. Over the last five days, the stock has gained 1.90%. Catalyst Pharmaceuticals Inc shares have risen nearly 18.30% since the year began. Nevertheless, the stocks have risen 56.76% over the past one year. While a 52-week high of $26.16 was reached on 03/24/25, a 52-week low of $14.47 was recorded on 01/08/25. SMA at 50 days reached $22.64, while 200 days put it at $20.43.
Levels Of Support And Resistance For CPRX Stock
The 24-hour chart illustrates a support level at 24.30, which if violated will result in even more drops to 23.91. On the upside, there is a resistance level at 25.03. A further resistance level may holdings at 25.37. The Relative Strength Index (RSI) on the 14-day chart is 62.78, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.75, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 24.76%. Stochastics %K at 78.67% indicates the stock is a holding.
How much short interest is there in Catalyst Pharmaceuticals Inc?
A steep rise in short interest was recorded in Catalyst Pharmaceuticals Inc stocks on 2025-03-14, growing by 1.51 million shares to a total of 7.23 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 5.72 million shares. There was a rise of 20.93%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 21, 2023 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
